A股異動 | 健友股份(603707.SH)升近6% 獲美國依諾肝素註冊批件
格隆匯12月2日丨健友股份(603707.SH)早盤快速拉昇上漲,一度大漲超8%。現升5.87%,報39.86元,成交量放大至1.58億元,最新總市值286.38億元。

健友股份昨日公告,獲得美國依諾肝素鈉注射液USP藥品註冊批件。平安證券點評稱,美國是全球最大的依諾肝素市場,公司依諾肝素憑藉原料藥優勢,預計上市後將搶佔10%-20%的市場份額。
同時公司積極佈局製劑出口,在研品種豐富,且多為中美雙報,迎來收穫季,維持“推薦”評級。此前公司前三季度盈利4.49億同比增長34.11%,注射劑出口發力值得期待。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.